SCHEMBL7687992

SCHEMBL7687992

C=CCNc1nc(NCC=C)c2scc(Br)c2n1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCI P41743 9/20 0.41
MEN1 O00255 2/20 0.39
KMT2A Q03164 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
CYP2D6 P10635 1/20 0.39
CYP2C19 P33261 1/20 0.39
INSR P06213 1/20 0.39
IGF1R P08069 1/20 0.39
FGFR1 P11362 1/20 0.39
KDR P35968 1/20 0.39
GAA P10253 1/20 0.38
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 2/20 0.35
LMNA P02545 1/20 0.35
HPGD P15428 1/20 0.35
MTOR P42345 1/20 0.35
HTT P42858 1/20 0.35
NCOA1 Q15788 1/20 0.35
NCOA3 Q9Y6Q9 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7687480 0.87 PRKCI (0.42) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7684270 0.85 ALDH1A1 (0.44) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7678942 0.85 KMT2A (0.39) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7683161 0.81 MEN1 (0.37) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7681398 0.80 PRKCI (0.40) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7682948 0.80 CYP1A2 (0.36) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7682019 0.80 PRKCI (0.38) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7683912 0.79 MEN1 (0.36) MEN1KMT2ACYP1A2CYP3A4CYP2D6
SCHEMBL7679176 0.78 PRKCI (0.44) PRKCIMEN1KMT2ACYP1A2CYP3A4
SCHEMBL7681312 0.78 PRKCI (0.41) PRKCIMEN1KMT2ACYP1A2CYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6339089-B2 ANTIHYPOXIC AGENTS; CHRONIC OBSTRUCTIVE PULMONARY DISEASE; VASOCONSTRICTION; REDUCES BLOOD PARTIAL PRESSURE OF CARBON DIOXIDE; RESPIRATORY DISORDERS; UNDER OXYGEN INHALATION TREATMENT FUJIREBIO INC. (JP) 2002-01-15 US disclosed
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME FUJIREBIO INC. (FUJIREBIO KABUSHIKI KAISHA) (JP) 2001-07-05 US disclosed
EP-0899263-A2 Fused pyrimidine derivatives and medicaments thereof for a blood oxygen partial pressure amelioration Fujirebio Inc. (JP) 1999-03-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010006969-A1 PYRIMIDINE NUCLEUS-CONTAINING COMPOUND AND A MEDICAMENT CONTAINING THE SAME FOR A BLOOD OXYGEN PARTIAL PRESSURE AMELIORATION, AND A METHOD FOR PREPARING THE SAME CYP11B2, CYP11B1, OAT PRKCI 2876/4885MEN1 2963/4885KMT2A 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.